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Context: Mitochondrial cytochrome P450scc converts cholesterol to pregnenolone in all steroido-
genic tissues. Although progesterone production from the fetally-derived placenta is necessary to
maintain pregnancy to term, four patients with mutations in the gene encoding P450scc
(CYP11A1), have been described, one in a 46,XX female and three in underandrogenized 46,XY
individuals, all with primary adrenal failure.
Objective:OuraimwastodeterminewhetherP450sccmutationsmightbefoundinotherchildren
and to explore genotype/phenotype correlations.
Methods and Patients: We performed mutational analysis of CYP11A1 in individuals with 46,XY
disorders of sex development and primary adrenal failure, followed by functional studies of
P450scc activity and of P450scc RNA splicing.
Results:Amongnine46,XYinfantswithadrenalfailureanddisorderedsexualdifferentiation,two
infants had compound heterozygous mutations in CYP11A1. One patient harbored the novel
P450sccmissensemutationsL141WandV415E,whichretained38and0%activity,respectively.The
other carried a CYP11A1 frameshift mutation c835delA (0% activity) and a splice site mutation
[IVS3(2-3)insT] that prevented correct splicing of P450scc mRNA.
Conclusions: P450scc deficiency is a recently recognized disorder that may be more frequent than
originally thought. The phenotypic spectrum ranges from severe loss-of-function mutations asso-
ciatedwithprematurity,completeunderandrogenization,andsevere,early-onsetadrenalfailure,
to partial deficiencies found in children born at term with clitoromegaly and later-onset adrenal
failure.Incontradistinctiontocongenitallipoidadrenalhyperplasiacausedbysteroidogenicacute
regulatoryproteinmutations,adrenalhyperplasiahasnotbeenreportedinanyofthesixpatients
with P450scc deficiency. (J Clin Endocrinol Metab 93: 696–702, 2008)
T
he first step in the biosynthesis of all steroid hormones is
theconversionofcholesteroltopregnenolone,catalyzed
by the mitochondrial enzyme P450scc (1). Deletion of the
single CYP11A1 gene encoding P450scc, occurring naturally
either in the rabbit (2) or in knockout mice (3), ablates all
steroidogenesis, demonstrating that there is only one gene
encoding only one enzyme with this activity. A clinical defect
intheproductionofallsteroidswasfirstreportedin1955(4),
and several studies of affected tissue indicated defective con-
version of cholesterol to pregnenolone (5–7), so that this dis-
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termed “20,22 desmolase deficiency” (for review, see Ref. 8).
However, studies of DNA from affected individuals demon-
stratedthattheCYP11A1geneencodingP450sccwasnormal
in this disease (9–12), and in 1995 it was shown that this
disease, more properly termed “congenital lipoid adrenal hy-
perplasia” (lipoid CAH) was caused by mutations in the gene
encoding the steroidogenic acute regulatory protein (StAR)
(13, 14).
Studies of lipoid CAH showed that only the acute stimu-
lationofsteroidogenesisrequiresStAR;intheabsenceofStAR
there is still a low level of StAR-independent steroidogenesis
(15), such as that seen in the placenta, which lacks StAR (16).
Thesuccessfuloutcomeofpregnanciesharboringfetuseswith
severe defects of adrenal and gonadal steroidogenesis, includ-
ingfetuseswithadrenalhypoplasiacongenitaduetomutation
of DAX-1 (17–20) or steroidogenic factor 1 (SF1) (21–23),
indicates that fetal steroidogenesis is not required for human
fetal development (24). By contrast, placental production of
progesteroneisessentialtosuppressuterinecontractility,per-
mitting pregnancy to progress. Thus, human pregnancy de-
pends on progesterone from the mother’s corpus luteum of
pregnancy during the first trimester, whereupon there is a
“luteo-placental shift” to production of progesterone by the
placentalsyncytiotrophoblasts,afetaltissue(25).Inthepreg-
nancies of some animals, such as the rabbit and rodent, pro-
gesterone is produced by the corpus luteum throughout preg-
nancy, so that ablation of P450scc remains compatible with
termgestation.Thus,ithadbeenthoughtthatinterferingwith
progesterone synthesis by the human placenta would result in
second trimester spontaneous abortion (26), but several cases
ofsevereP450sccmutationshavenowbeenreported(27–30).
Becausesuchcasesrepresentnovelexperimentsofnaturethat
probe the roles of fetal steroidogenesis in human pregnancy,
there is substantial interest in the rare patients with genetic
defects in P450scc. We now report the clinical, molecular
genetic, and functional analysis of P450scc mutations in two
additional patients and review the findings in all reported
patients with P450scc defects.
Subjects and Methods
Mutational analysis
With Institutional Review Board approval and informed consent,
genomicDNAwasextractedbystandardmethodsfromperipheralblood
leukocytesofnineinfantswith46,XYdisordersofsexualdifferentiation
and primary adrenal failure. Among these nine infants, four were pre-
term (two with mild hypospadias, one with clitoromegaly, and one with
normal female genitalia), and five were full term (one with ambiguous
genitalia and four with female genitalia; two of these had P450scc mu-
tations).MutationsinStARandSF1wereexcludedbyDNAsequencing,
as described (15, 22).
All nine exons and all splice sites of CYP11A1 were PCR-amplified
using variations on conditions reported previously (27, 29). PCR prod-
ucts were purified using 1 U/l Exonuclease I (New England Biolabs,
Beverly, MA) and 0.1 U/l shrimp alkaline phosphatase (USB Corp.,
Cleveland, OH) and then subjected to direct sequencing using BigDye
terminator v1.1 (Applied Biosystems, Foster City, CA) and a Mega-
BACE1000capillaryDNAsequencer(AmershamBiosciencesInc.,Little
Chalfont, UK). Sequence Analyser v3.0 (Amersham Biosciences) and
Sequencher v4.1 (Gene Codes Corp., Ann Arbor, MI) were used to an-
alyze the data.
Compoundheterozygousmutationswereconfirmedbystudyingparen-
tal DNA, as well as by subcloning PCR products into a TA-cloning vector
(Invitrogen, Carlsbad, CA) and sequencing independent clones. Genscan
splicepredictionsoftware(http://genes.mit.edu/GENSCAN.html)wasused
to assess the consequences of the splice site mutation detected.
Functional studies of P450scc activity
The P450scc moiety of the F2 plasmid expressing a fusion protein
(H2N-P450scc-adrenodoxin reductase-adrenodoxin-COOH) of the hu-
man cholesterol side chain cleavage system (31) was mutagenized by
PCR-based,site-directedmutagenesisasdescribed(27)usingtheprimers
shown in Table 1. The PCR conditions were: 95 C for 1 min, 15 cycles
of 95 C for 30 sec, 55 C for 1 min, and 68 C for 16 min. Mutagenized
cDNA plasmids were sequenced in their entirety before functional
studies.
Wild-type and mutant P450scc function was assessed using an in
vitro system with pregnenolone production as a measure of enzyme ac-
tivity. Nonsteroidogenic COS-1 cells were cultured to 90–95% conflu-
ence at 37 C in 5% CO2 in DMEM/Ham’s 21 medium supplemented
with 10% fetal bovine serum and 50 g/ml gentamycin and transfected
with 1 g of either the wild-type or mutant F2 plasmid, using Lipo-
fectamine 2000 (Invitrogen), as described (13). Culture media were
treatedwith5g/ml22R-hydroxycholesterol,whichbypassestheaction
of StAR and is converted to pregnenolone by P450scc (31). Media were
collected 48 h later, and pregnenolone production was assayed by RIA
TABLE 1. Oligonucleotide sequences
Sequence (5-3) Purpose
Nucleotide change (codon sequence)
422T3G (L141W) Sense: CCATAGGAGTCCTGTGGAAGAAGTCGGCAGC
Antisense: GCTGCCGACTTCTTCCACAGGACTCCTATGG
1244T3A (V415E) Sense: CTGCCAAGACACTGGAGCAAGTGGCCATCTA
Antisense: TAGATGGCCACTTGCTCCAGTGTCTTGGCAG
c835delA Sense: TCAGTAAAGCTGACTATACACCCAGAACTTC
Antisense: GAAGTTCTGGGTGTATAGTCAGCTTTACTGA
Name for minigene experiment
SCC-x3/x4-F AGTAGGATCCGAAGTCGGCAGCCTGGAAGAA Cloning
SCC-x3/x4-R TATCCTCGAGCTTTACTGAAAATCACGTCCCA Cloning
IVS3- S CTTTGCCTTTGAGTGTTAAGGGGGCTTGCACCT Mutagenesis
IVS3-AS AGGTGCAAGCCCCCTTAACACTCAAAGGCAAAG Mutagenesis
GAPDH-sense AGAAGGCTGGGGCTCATTT PCR
GAPDH-antisense ACAGTCTTCTGGGTGGCAGT PCR
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(32). Data are presented as the mean  SEM for four independent exper-
iments, each performed in triplicate.
Minigene construction and splicing analysis
Asegmentofthewild-typehumanCYP11A1geneencodingP450scc,
consisting of exon 3, intron 3, and exon 4, was amplified by PCR using
oligonucleotides scc-x3/x4 F and R (Table 1). PCR was done with pfu
polymerase (Stratagene, La Jolla, CA), starting at 95 C for 5 min, fol-
lowed by 15 touchdown cycles starting at 95 C for 30 sec, followed by
a gradient of 67 to 60 C with the temperature reduced by 0.5 C for each
30-sec cycle, concluding with 90 sec at 72 C. This was followed by 35
PCRcyclesof95Cfor30sec,60Cfor30sec,and72Cfor30sec,ending
with a final extension at 72 C for 7 min. The PCR product was cleaved
withBamHIandXhoIandclonedintothecorrespondingsitesofpcDNA
3.1, placing the construct under the transcriptional regulation of the T7
promoter in the vector. The intron 3 mutant was created by PCR-based
site-directed mutagenesis of this wild-type plasmid using the oligonucle-
otides listed in Table 1. The wild-type and mutant vectors were con-
firmed by sequencing using GenBank sequences NC_000015.8 (33) as
the genomic reference and NM_000781 (34) as the mRNA reference.
HeLa cells were grown to 50–80% confluence at 37 C in 5% CO2
in DMEM/Ham’s 21 medium supplemented with 10% fetal bovine se-
rumand50g/mlgentamycin.Thewild-typeandmutantminigenecon-
structs (2 g) were transfected into HeLa cells using 16 l Enhancer and
60 l Effectene transfection reagents (QIAGEN, Hilden, Germany). Af-
ter transfection for 20 h, the cells were washed with PBS and incubated
in fresh medium for an additional 24 h; then total cellular RNA was
prepared using TRI reagent (Molecular Research Center, Cincinnati,
OH). The RNA was treated with DNaseI to degrade any contaminating
genomic DNA; 1 l2 5m M EDTA was added to stop the reaction, and
the DNaseI was heat-inactivated at 65 C for 10 min; the RNA was then
usedastemplateforcDNAsynthesisusingreversetranscriptase(Invitro-
gen). The single-stranded cDNA was used as template for PCR ampli-
fication using vector-specific primers (Invitrogen) and primers for
GAPDH as an internal control (Table 1). PCR was started at 95 C for 2
min, followed by 15 touchdown cycles beginning with 95 C for 30 sec,
followed by a gradient of 57 to 50 C with the temperature reduced 0.5
C for each 30 sec cycle, and 72 C for 90 sec. This was followed by 40
cycles of PCR of 95 C for 30 sec, 50 C for 30 sec, and 72 C for 90 sec,
ending with a final extension at 72 C for 7 min.
Case Reports
Four previous patients have been reported with P450scc defi-
ciency (27–30), hence our cases are termed patients 5 and 6.
Patient 5
Patient 5 is a phenotypically normal female without clitoro-
megalybornattermafteranuneventfulpregnancy;birthweight
was 3.1 kg and her clinical and hormonal data have been re-
ported (35). There was no maternal history of miscarriage, but
an older sibling had died from pneumonia at 5 months of age.
Patient5becamelethargicandhypoglycemic(10mg/dl)at9hof
age and developed hyperkalemia (7.1 mmol/liter) and hypona-
tremia(121mmol/liter)duringthefirstweekoflife.At9dofage
her plasma ACTH was grossly elevated (1000 pg/ml), cortisol
was 8.5 g/dl but did not respond to cosyntropin (peak, 9.2
g/dl), and other measured steroids (in nanograms per deciliter)
were low (compared with reference ranges): 17OH-preg-
nenolone41(70–850);aldosterone4.6(5–175);17OH-proges-
terone 9.0 (60–150); and dehydroepiandrosterone (DHEA) 29
(50–760).Sherespondedwelltotreatmentwithhydrocortisone,
9-fludrocortisone, and salt.
At 4.5 yr, pelvic ultrasonography revealed bilateral intraab-
dominal gonads and no uterus. Karyotype was 46,XY. Basal
gonadotropins were elevated (FSH 18 IU/liter, LH 27 IU/liter)
andadministrationof5000Uofhumanchorionicgonadotropin
(hCG) daily for 3 d produced no detectable testosterone. Anti-
Mu ¨llerianhormone(AMH)was9.9ng/ml(normalrange48–83
ng/ml),indicatingSertolicellfailure.Thetesteswereremovedat
8 yr of age, and estrogen replacement was initiated at 11 yr to
induce feminization.
Patient 6
The mother of patient 6 had a prior miscarriage and after the
birth of patient 6, had another miscarriage at 10–12 wk gesta-
tionofa46,XYfetuswithunfusedlabioscrotalfolds.Duringthe
pregnancy with patient 6, the mother had low serum estriol and
high hCG; amniocentesis showed that the fetus was 46,XY. La-
bor was induced at 39 wk, and failure to progress necessitated a
cesarean section. At birth, the weight was 2.98 kg and the ex-
ternal genitalia were normal female; no gonads, internal repro-
ductive structures, or adrenals were identified by ultrasound or
magnetic resonance imaging (MRI), and a genitogram revealed
a blind vaginal pouch. At 6–7 d of age she had hypoglycemia (6
mg/dl), hyponatremia (125 mmol/liter), hyperkalemia (6.1
mmol/liter), and undetectable plasma cortisol (1 g/dl). All
steroidvaluesobtainedbetween4and9dofagewerelow(com-
pared with reference ranges in parentheses; all values in nano-
grams per deciliter at Endocrine Sciences, Tarzana, CA): preg-
nenolone 127 (150–2000); progesterone 10 (84–1360);
17OH-progesterone20(7–77);DHEA121(65–1250);andro-
stenedione 25 (20–290); testosterone 3 (75–400); dihydrotes-
tosterone2(5–60).AMHwaslowbutdetectable(11.0ng/ml;
reference range 16–49), suggesting the presence of some Sertoli
cells. She responded well to treatment with hydrocortisone, 9-
fluorocortisone, and salt. Despite the absent gonadal steroids,
gonadotropins were undetectable in the first 12 d of life; the
reason for this is not clear. At 8 wk of age, after administration
ofluprolide(10g/kg),LHwasonly0.87IU/liter,free-subunit
was 1.0 ng/ml, and androstenedione, DHEA, 17OH-progester-
one, and testosterone did not rise after administration of three
doses of 1500 IU hCG given every other day. Adrenal failure
combinedwithhypogonadotropichypogonadismmightsuggest
a defect in DAX-1, and combined adrenal and gonadal failure
mightsuggestalesioninSF1(23),butthesequencesofbothgenes
were normal. Patient 6 also had a tethered spinal cord due to a
lipoma, hyperlordosis, strabismus, central hypothyroidism, and
subnormal GH secretion. At 9 yr, FSH was 73 IU/liter and LH
was 4 IU/liter, suggesting primary gonadal failure rather than
hypogonadotropic hypogonadism. Consistent with this, AMH
was only 1.2 ng/ml (normal range 34–60 ng/ml at 7–8 yr). A
repeat MRI scan detected no adrenal or gonadal tissue. How-
ever, because AMH remained detectable, laparoscopy was per-
formedandbilateralatrophictesteswereremoved,oneofwhich
had a small Sertoli cell adenoma.
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Mutational analysis
Patient 5 was a compound heterozygote for the novel
CYP11A1 missense mutations L141W (c422TG), inherited
from the mother, and V415E (c1244TA), inherited from the
father.Patient6wasacompoundheterozygotefortheframeshift
mutation c835delA inherited from the mother and for the splice
site mutation IVS3(2–3)insT inherited from the father. Ho-
mozygosity for the c835delA mutation was previously reported
in patient 3 (29).
Studies of P450scc enzyme activity
The activity of P450scc requires the presence of the electron-
transferproteins,adrenodoxin,andadrenodoxinreductase(36).
Because P450scc activity is crucially dependent on the molar
ratioofeachofthesethreecomponentsand,indifferentsystems,
both adrenodoxin (31, 37) and adrenodoxin reductase (38, 39)
can be limiting, a single plasmid (F2) was used that expresses a
fusion protein of the three components of the cholesterol side
chain cleavage system (H2N-P450scc-adrenodoxin reductase-
adrenodoxin-COOH) with a fixed molar ratio (1:1:1) (31). Us-
ing this system ensures that any variations in mutant P450scc
activity seen in transfection assays is due to the amino acid
change in the mutation rather than to variations in the level of
cofactor expression.
COS-1 cells expressing wild-type F2 plasmid made 1350 
189ngpregnenolone/mlculturemedium(mean SEM),whereas
cells transfected with the empty vector produced no detectable
pregnenolone. The L141W mutant found in patient 5 produced
520  78 ng pregnenolone/ml (38.5% of wild-type F2 protein),
whereas the V415E mutation also found in patient 5 lacked any
detectable ability to convert cholesterol to pregnenolone. Simi-
larly, when the c835delA mutation identified in patient 6 was
introducedintotheP450sccmoietyoftheF2plasmid,noactivity
was detected (Fig. 1).
Minigene analysis of the splice site mutation
The IVS3(2-3)insT mutation found in patient 6 introduces
an additional thymidine after the second base in the third intron
sothatTTGGAGTgtaagggbecomesTTGGAGTgttaaggg.This
insertion is predicted to disrupt the gtaaggg splice donor site, so
that the intronic sequence will be retained in the mRNA. The
retention of the intron with the additional thymidine would cre-
ate a TAA stop codon: TTG GAG TGT TAA ggg that would
result in a truncated protein devoid of activity. Alternatively, it
is possible that some transcripts might be spliced correctly. To
distinguish between these possibilities, we constructed a “mini-
gene”comprisingexon3,intron3,andexon4andcomparedits
splicing when the intron 3 sequence was either wild-type or car-
ried the mutation found in patient 6.
PCR amplification of the RNA produced from the transcrip-
tionofthewild-typeminigeneshowedthatintron3wascorrectly
spliced,yieldingaproductofthepredictedsize(580bp)(Fig.2).
By contrast, PCR amplification of the RNA produced by the
mutant minigene produced a product of 1631 bp and no 580 bp
productwasseen,indicatingthatthesequencescorrespondingto
intron 3 had been retained in the RNA. Thus the intronic mu-
tationfoundinpatient6preventscorrectsplicingoftheP450scc
RNA, so that functional protein cannot be made.
Discussion
The maintenance of human pregnancy requires progesterone,
which suppresses uterine contractility, permitting gestation to
proceed to term (25, 40, 41), and interruption of the action of
progesterone will induce abortion. Because P450scc is the only
known enzyme that can convert cholesterol to pregnenolone
(1–3),ithasbeenthoughtthatinactivatingmutationsofP450scc
or of any other factor required for placental synthesis of pro-
gesterone would be incompatible with term human gestation
(26). Consistent with this, no mutations have been reported in
ferredoxin, ferredoxin reductase, or the placental isozyme of
3-hydroxysteroid dehydrogenase. However, four previous pa-
FIG. 1. Activities of P450scc mutations. COS-1 cells were transfected with either
wild-type or mutant F2 plasmid. Pregnenolone secreted into the culture medium
was determined by RIA. Empty vector was used as a negative control, and the
StAR-independent substrate 22R-hydroxycholesterol was added to the culture
medium. Values are the mean  SEM from four independent transfection
experiments, each performed in triplicate.
FIG. 2. Minigene experiment. HeLa cells were transfected with empty pcDNA3.1
vector, or vector expressing the wild-type or mutant CYP11A1 minigene
construct. Total RNA from the transfected HeLa cells were used for RT-PCR,
showing the expected 580-bp product from the wild-type construct but no
correctly spliced product from the mutant. PCR of GAPDH RNA was used as an
internal control, producing a 247-bp PCR fragment.
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we now add two more. Review of these cases shows imprecise
correlation between the clinical findings and the enzymology of
the P450scc mutations identified in these individuals (Table 2).
Patients 1 (27), 2, (28), and 4 (30) all came to medical attention
well after the newborn period (9 months to 4 yr of age) and all
had P450scc lesions that retained substantial activity: patient 1
wasamanifestingheterozygoteforamutationdevoidofactivity
and hence would be predicted to have about 50% of activity
(from the normal allele). Patient 2 carried a missense mutation
(R353W) with about 8% of activity on one allele, and the other
allele carried a P450scc mRNA splicing defect that generated a
small amount of correctly spliced RNA, but the proportion of
correctlytoincorrectlysplicedRNAwasnotquantitated.Patient
4 had two missense mutations, A359V and R353W, reported to
retain11.7and2.8%ofactivity,respectively,althoughthesame
group reported that R353W retained 8.1% of activity in their
report of patient 2. By contrast, patient 3 was homozygous for
the frameshift mutation c835delA, predicted to cause the pre-
maturestopcodonL288X;wehavenowtestedthisframeshiftin
vitro,becauseitwasalsofoundinpatient6,andhaveshownthat
it is devoid of detectable activity. Consistent with the lack of
detectable enzymatic activity using an in vitro assay, patient 3
had the most severe clinical course, being born at 31 wk and
having profound neonatal adrenal failure.
Patients 5 and 6, reported here, also had adrenal failure in the
firstweekoflifebuthadsucceededinreachingtermgestation,sug-
gesting that some placental progesterone was synthesized through-
out pregnancy. Patient 6 had mutations that eliminated detectable
activity, yet she reached term gestation. However, the functional
datainpatient5aremoreconfusing.TheL141Wmutationretained
38.5%ofactivitysothatintheheterozygousstateonewouldexpect
about19%ofnetactivity.Thisissubstantiallygreateractivitythan
was seen in patients 2 and 4, yet the clinical presentation was sub-
stantially more severe. In sum, the data in the six reported patients
with P450scc deficiency (Table 2) show a spectrum of clinical pre-
sentations from intractable early labor and prematurity to adrenal
insufficiency in early childhood. The phenotype/genotype correla-
tions are poor, but the precise reasons for this are unknown.
P450scc deficiency is a novel, rare disorder that can present as
acute adrenal insufficiency at any time from infancy to early child-
hood. In all cases, ACTH and plasma renin activity are grossly
elevatedandadrenalsteroidsareinappropriatelyloworabsent;the
46,XY patients have female external genitalia, sometimes with cli-
toromegaly. In contradistinction to the massive adrenal enlarge-
ment typically seen in congenital lipoid adrenal hyperplasia caused
by mutations in StAR (7), none of the six patients with P450scc
deficiencyhasbeenreportedtohaveadrenalhyperplasia.Although
asmallnumberofpatientswithStARmutationshavenormal-sized
adrenals (42, 43), this may be useful in distinguishing these disor-
ders. Affected tissue has not been available to determine whether
P450scc-deficientadrenalscanrespondtoACTHinvitro.Withthe
exception of patient 3 (29) and patient 6, described here, other
reported patients have had at least one allele that conferred some
activity. This would seem to explain the term gestation because
P450scc is needed to make the progesterone required to maintain
pregnancy. Patient 3 (29) remains enigmatic; the survival of that
pregnancy to 31 wk may have been caused by an unusually long
survival of the progesterone biosynthetic capacity of the maternal
corpus luteum, which eventually involuted, causing premature la-
bor. Several patients have had other clinical problems (absent cor-
pus callosum in patient 4, tethered spinal cord in patient 6, short
statureinpatients3(O.Hiort,personalcommunication)and6,but
a link to P450scc deficiency is not established for any of these con-
ditions. Additional cases, especially those studied hormonally dur-
ing pregnancy, may provide further information about the hor-
monalcontrolofparturitionandilluminatethepathophysiologyof
P450scc deficiency.
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